Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Proton pump inhibitors Stories

18af6de42d3bd1b81fbcc64a9d8eb4ab
2009-04-09 07:15:00

The surprising results of a recent study indicate that the decades long medical practice of prescribing heartburn medications to patients with asthma is ineffective. The new study found that the popular heartburn drug Nexium, also known as the purple pill, did not reduce asthma symptoms in patients who were not also suffering from heartburn.  An estimated 2.5 to 5 million suffer from a combination of asthma and gastroesophageal reflux, commonly referred to as heartburn. For at least the...

2009-04-08 16:00:00

--Practice Changing Study Calls on Doctors to Stop Prescribing Potent Heartburn Medications to Asthma Patients Without Frequent Symptoms of Gastric Reflux-- WASHINGTON, April 8 /PRNewswire-USNewswire/ -- For nearly 20 years, it was believed that severe asthma symptoms such as coughing, wheezing and breathlessness were triggered in part by acid reflux. A new study conducted by the American Lung Association's Asthma Clinical Research Centers (ACRC) finds the longstanding practice of...

2009-02-23 14:00:00

DEERFIELD, Ill., Feb. 23 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. today announced that KAPIDEX(TM) (dexlansoprazole) delayed release capsules are now available in pharmacies across the U.S. KAPIDEX, available in 30 mg and 60 mg doses, was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of...

2009-01-30 19:13:00

First proton pump inhibitor (PPI) with a Dual Delayed Release(TM) (DDR) formulation DEERFIELD, Ill., and OSAKA, Japan, Jan. 30 /PRNewswire/ -- Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration (FDA) approved KAPIDEX(TM) (dexlansoprazole) delayed release capsules for the once-daily, oral treatment of heartburn associated with symptomatic non-erosive Gastroesophageal...

2009-01-29 08:45:48

Patients taking the common cardiac drug clopidogrel following a heart attack are at a significantly higher risk of a recurrence if they are also taking widely used acid-lowering medications called proton pump inhibitors, a new study published online in CMAJ has found (http://www.cmaj.ca/cgi/rapidpdf/cmaj.082001).The study, conducted over 6 years in thousands of heart attack patients aged 66 years and older, found a significantly increased risk of readmission for heart attacks if patients were...

2009-01-23 07:00:00

PITTSBURGH, Jan. 23 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Omeprazole Delayed-release (DR) Capsules USP, 40 mg, the generic version of AstraZeneca's Prilosec(R) DR Capsules. Omeprazole DR Capsules are indicated for the treatment of peptic ulcers and gastroesophageal reflux disease...

2008-12-19 07:00:00

-Filing also includes age appropriate formulation of 2.5 mg and 5 mg strengths of NEXIUM for Delayed-Release Oral Suspension- WILMINGTON, Del., Dec. 19 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for NEXIUM(R) (esomeprazole magnesium) to seek approval for the short-term (up to 6 weeks) treatment of gastroesophageal reflux disease (GERD) in pediatric patients ages...

ed1567a59739fddcaa08d525f8f366c71
2008-11-12 07:55:00

According to a new study, stent patients who take the blood thinner Plavix combined with heartburn drugs may face a greater risk of heart attack.Researchers concluded patients who took Plavix with popular prescription heartburn drugs, including AstraZeneca's Nexium, were more likely to be hospitalized for a heart attack, stroke, chest pain or a coronary artery bypass operation than those who took Plavix alone.A stent is a wire-mesh tube used to prop open arteries after they have been cleared...

2008-11-11 15:00:22

FRANKLIN LAKES, N.J., Nov. 11 /PRNewswire-FirstCall/ -- Medco Health Solutions, Inc. today presented a study at the 2008 Scientific Sessions of the American Heart Association that showed an increased risk for major cardiovascular events in patients taking clopidogrel (the active ingredient in Plavix) and proton pump inhibitors (PPIs) together. In the largest study of its kind to date, researchers at Medco report that PPIs inhibit the effectiveness of clopidogrel, the number two...

2008-10-17 06:00:08

POZEN Inc. (NASDAQ: POZN), today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that, as part of the FDA's on-going discussions with the Company and their review of both the Special Protocol Assessment (SPA) for PA32540 and the Statistical Analysis Plan (SAP) for PN 400, the FDA is conducting an internal review on the acceptability of using endoscopic gastric ulcers as a primary endpoint in clinical studies. The Company has been advised by the FDA that an...